Publisher: Parenteral Drug Association (PDA) Publication Year: 2022 (Originally published as a draft, finalized recently) Subject: Validation and qualification of dry heat depyrogenation processes used in the pharmaceutical industry.
You cannot find a free, legal PDF of TR-82. PDA is a non-profit, but it funds its research through report sales. To get the PDF:
PDA TR-82 does not discard the BET—it refines its interpretation. It acknowledges that absence of detection is not absence of danger. For biotech and pharma quality units, adopting TR-82’s principles means moving from a one-time assay to a product-lifecycle risk management approach.
In an era of increasingly complex biologics, novel excipients, and sensitive routes of administration, TR-82 isn’t just a technical report—it’s an essential update to the safety playbook.
PDA Technical Report No. 82 (2020): “Low Endotoxin Recovery” is available for download from the Parenteral Drug Association (PDA).
Introduction
The PDA Technical Report 82 (TR 82) is a comprehensive guide published by Parenteral Drug Association (PDA), a leading global organization in the field of pharmaceutical science and technology. The report provides guidance on the best practices for the evaluation and control of extractables and leachables in pharmaceutical products.
What are Extractables and Leachables?
Extractables are chemical compounds that can be extracted from materials, such as packaging components, equipment, or processing aids, using a solvent. Leachables, on the other hand, are chemical compounds that migrate from materials into a pharmaceutical product, potentially affecting its quality, safety, and efficacy.
Importance of Controlling Extractables and Leachables pda technical report 82 pdf
The presence of extractables and leachables in pharmaceutical products can pose significant risks to patient safety and product quality. These contaminants can affect the stability, purity, and potency of the drug product, leading to adverse reactions, reduced efficacy, or even product recalls.
PDA Technical Report 82 (TR 82)
The PDA TR 82 provides a detailed framework for the evaluation and control of extractables and leachables in pharmaceutical products. The report covers the following key areas:
Benefits of PDA TR 82
The PDA TR 82 provides several benefits to pharmaceutical manufacturers, including:
Conclusion
The PDA Technical Report 82 is a valuable resource for pharmaceutical manufacturers, providing guidance on the evaluation and control of extractables and leachables. By following the best practices outlined in the report, manufacturers can ensure patient safety, product quality, and regulatory compliance, ultimately contributing to the development of high-quality pharmaceutical products.
If you'd like me to add or modify anything, please let me know!
The PDF version of PDA Technical Report 82 can be obtained from the PDA website or through other online sources. Title: PDA Technical Report No
PDA Technical Report No. 82 (TR 82), titled "Low Endotoxin Recovery" (LER), provides a comprehensive framework for identifying, studying, and mitigating the masking of endotoxins in biologic drug products.
A standout feature of TR 82 is its Standardized Protocol for LER Hold-Time Studies. The Hold-Time Study Feature
This feature provides a non-prescriptive but detailed "roadmap" for companies to prove their endotoxin test methods are reliable over time. Core Requirements Definition of LER: Standardizes LER as a failure to recover
of spiked endotoxin activity over time in an undiluted sample.
Spiking Guidelines: Recommends using Control Standard Endotoxin (CSE) or Reference Standard Endotoxin (RSE) for primary studies.
Testing Conditions: Outlines specific parameters for storage time, temperature, and container types to reflect real-world manufacturing.
Data Interpretation: Establishes that LER is confirmed when two consecutive time points fall below the 50% recovery threshold. Additional Key Sections PDA technical report on low endotoxin recovery | Lonza
The report outlines a lifecycle approach to validation, consisting of:
The document is a proprietary technical report owned by the PDA. How to Legitimately Obtain the PDF You cannot
TR-82 (2020) moves beyond anecdotal warnings into actionable guidance:
1. A Clear, Risk-Based Workflow
The report doesn’t demand LER testing for every product. Instead, it provides a decision tree:
If yes, TR‑82 recommends an LER evaluation.
2. Standardized Methodologies
The report details protocols for “spike and hold” studies using a relevant container-closure system. Crucially, it introduces two recovery benchmarks:
A significant drop in recovery (>50% loss) without corresponding loss in activity signals LER potential.
3. Bridging to Biological Activity
TR-82 emphasizes that LER is not simply an assay artifact. It recommends orthogonal methods (e.g., in vitro pyrogen test using human whole blood or monocyte activation test) to determine whether undetected endotoxin retains pyrogenicity.
4. Regulatory Alignment
The report aligns with USP <85>, <86>, and <1085> while addressing gaps left by compendial methods. It helps firms justify additional controls or alternative testing strategies in regulatory filings.
Based on the recommendations in the PDF, here is how to operationalize the report: